AcelRx Names New CEO
This article was originally published in Scrip
AcelRx Pharmaceuticals Inc. has appointed Howard B. Rosen CEO after he served as interim CEO for the company – effective April 1, 2016. Rosen previously held senior-level general management positions and functional roles at Gilead Sciences Inc. and ALZA Corp. Most recently he was interim CEO of Pearl Therapeutics (acquired by AstraZeneca) and has served on AcelRx's board of directors since 2008. Rosen is also on the board for Alcobra Ltd.
Register for our free email digests: